Proscia Wins 2025 MedTech Breakthrough Award
Proscia: Honored alongside Abbott, Johnson & Johnson, IQVIA, and ŌURA
PHILADELPHIA —May 8, 2025—Proscia®, a software company leading pathology’s transition to digital and AI, has been named a winner in the 2025 MedTech Breakthrough Awards program celebrating the world’s most outstanding companies, products, and people in medical technology. Its Concentriq® AP-Dx* software platform was recognized for innovation, performance, value, and impact as digital pathology increasingly enters the mainstream.
Laboratories initially made the shift from microscopes to data-rich images to diagnose patients with diseases like cancer amid a supply and demand challenge; global cancer cases are expected to increase by 77% to 35.3 million cases by 2050¹ while the pathologist population declined by 17.5% in a decade2. Accelerated by the rise of precision medicine and recent advancements in AI, digital pathology is now additionally enabling laboratories to better inform up to 70% of clinical decisions and capitalize on new opportunities to collaborate with life sciences organizations on the next novel therapies and diagnostics.
“This is an incredibly exciting time for pathologists, patients, our industry, and our company,” said David West, Proscia’s CEO. “Being honored by MedTech Breakthrough alongside some of the most prominent names in healthcare, as digital pathology quickly becomes the standard of care, reinforces Proscia’s leadership in driving this transformation. We are delivering the software that is rewiring how the world diagnoses disease.”
Concentriq AP-Dx is a robust platform that enables pathologists to view, share, manage, and interpret pathology images. In doing so, it provides the tools for driving quality and efficiency gains while laying the foundation for AI. Trusted by major laboratories and health systems around the world, Concentriq AP-Dx is on track to diagnose more than 22,000 patients per day in 2025.
Now in its ninth year, the MedTech Breakthrough Awards aims to deliver the most comprehensive analysis of the digital health and medical technology industries. Proscia was selected from more than 4,500 nominations from around the world and recognized alongside Abbott, IQVIA, Johnson & Johnson, Medtronic, Nike Training Club, and ŌURA among other top companies and startups.
*Concentriq AP-Dx is intended for diagnostic use with the Hamamatsu NanoZoomer S360MD Slide scanner in the U.S. and with additional validated scanners in other markets. Concentriq AP-Dx is not intended for use with frozen sections, cytology, or non-FFPE hematopathology specimens. It is the responsibility of a qualified pathologist to employ appropriate procedures and safeguards to assure the quality of the images obtained and the validity of the interpretation of images using Concentriq AP-Dx.
About Proscia
Proscia is a software company accelerating pathology’s transition to a digital, data-driven discipline and enabling AI to advance precision medicine. Its Concentriq enterprise pathology platform, precision medicine AI portfolio, and real-world data fuel the development and use of novel therapies and diagnostics to drive the fight against humanity’s most challenging diseases, like cancer. 16 of the top 20 pharmaceutical companies and a global network of diagnostic laboratories rely on Proscia’s solutions each day. The company has FDA 510(k) clearance and CE-IVDR certification for its diagnostic software. For more information, visit proscia.com, and follow Proscia on LinkedIn and X.
1. Bizuayehu HM, Ahmed KY, Kibret GD, et al. Global Disparities of Cancer and Its Projected Burden in 2050. JAMA Netw Open. 2024;7(11):e2443198. doi:10.1001/jamanetworkopen.2024.43198
2. DM, Colgan TJ, Leung ST, Timmons CF, Park JY. Trends in the US and Canadian Pathologist Workforces From 2007 to 2017. JAMA Netw Open. 2019 May 3;2(5):e194337. doi: 10.1001/jamanetworkopen.2019.4337. PMID: 31150073; PMCID: PMC6547243.
SOURCE: Proscia
